Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)

Trial Profile

A multicenter, randomized controlled trial for the efficacy and safety of tocilizumab in the treatment of new coronavirus pneumonia (COVID-19)

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Jun 2020

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications COVID 2019 infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Mar 2020 New trial record

Trial Overview


This study is designed to evaluate the efficacy and safety of tocilizumab in treating regular patients with new coronavirus pneumonia (COVID-19) (including severe risk factors) and critical new coronavirus pneumonia (NCP) patients.

Primary Endpoints

Other Endpoints

mortality;Ventilator utilization;Hospitalization day; [1]

Diseases Treated

Indication Qualifiers Patient Segments
COVID 2019 infections treatment -


  • Subject Type patients
  • Number

    Planned: 188

  • Sex male & female
  • Age Group 18-85 years; adult; elderly

Patient Inclusion Criteria

1. The patients who were diagnosed with the common type of NCP (including severe risk factors) and severe cases of new coronavirus pneumonia; 2. Aged 18 to 85 years; 3. IL-6 elevated (using Elisa method, using the same company kit); 4. Patients or authorized family members volunteered to participate in this study and signed informed consent. Definition of Novel Coronavirus Pneumonia (NCP) clinical cases: 1. Regular patients with NCP (including severe risk factors): patients with dual pulmonary lesions based on common NCP clinical symptoms accompanied by fever or no fever; 2. Critical NCP patient: Refer to the "New Coronavirus Pneumonia Diagnosis and Treatment Plan (Fifth Edition)" formulated by the National Health Commission.

Patient Exclusion Criteria

1. Patients who are participating in other drug clinical trials; 2. Pregnant or lactating women; 3. ALT / AST> 5 ULN, neutrophils <0.5, platelets less than 50; 4. Definite diagnosis of rheumatic immune-related diseases; 5. Long-term oral anti-rejection or immunomodulatory drugs; 6. Hypersensitivity to tocilizumab or any excipients; 7. Patients with active pulmonary tuberculosis, with definite bacterial and fungal infections.

Trial Details


Identifier Owner
ChiCTR2000029765 Chinese Clinical Trial Register
2020-XG(H)-008 -


  • Affiliations Roche

Trial Dates

  • Initiation Dates

    Actual : 10 Feb 2020

  • End Dates

    Planned : 10 May 2020

Other Details

  • Design multicentre; parallel; prospective; randomised
  • Phase of Trial Phase IV
  • Location China
  • Focus Therapeutic Use


Drugs Route Formulation
TocilizumabPrimary Drug Intravenous

control group:conventional therapy;Experience group:conventional therapy+tocilizumab;

Trial Centres


Centre Name Location Trial Centre Country
Department of science and technology of Anhui Province
The First Affiliated Hospital of University of science and technology of China (Anhui Provincial Hospital)
17 Lujiang Road, Luyang District, Hefei, Anhui, China
show details
Hefei China

Trial History

Event Date Event Type Comment
17 Jun 2020 Other trial event Last checked against China Clinical Trials Register record. Updated 17 Jun 2020
11 Mar 2020 New trial record New trial record Updated 11 Mar 2020


  1. Chinese Clinical Trial Register. Trial-Reg 2016;.

    Available from: URL: http://www.chictr.org
  2. Can-Fite BioPharma. Can-Fite Updates on Clinical Milestone for its Phase III Rheumatoid Arthritis Study with Piclidenoson; Drugs Combating Rheumatoid Arthritis are Currently Introduced for the Treatment of the Coronavirus. Media-Rel 2020;.

    Media Release
Back to top